LUMINITY

This brand name is authorized in Austria, Estonia, Spain, Croatia, Ireland, Italy, Lithuania, Poland, Romania, United Kingdom

Active ingredients

The drug LUMINITY contains one active pharmaceutical ingredient (API):

1 Perflutren UNII CK0N3WH0SR - PERFLUTREN

When used in conjunction with diagnostic ultrasound, perflutren provides opacification of cardiac chambers, improvement in delineation of endocardial borders, enhancement of the Doppler signal, and visualisation of wall motion and blood flow within the heart. Read about Perflutren

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
LUMINITY Gas and solvent for dispersion for injection/infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
V08DA04		V Various → V08 Contrast media → V08D Ultrasound contrast media → V08DA Ultrasound contrast media
Discover more medicines within V08DA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1266869, 1537905
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 06361001
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 135637
Country: IT	Agenzia del Farmaco	Identifier(s): 037379017, 037379029
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1029638, 1029639
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100311659
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W54777001, W54777002